STATEMENT 2025

Ferring Pharmaceuticals announces optimisation of operations to accelerate growth

By celia in STATEMENT 2025 on 07 October 2025

Ferring announces new Ambition, Enterprise Model and Executive Committee composition to accelerate growth and innovation

By celia in STATEMENT 2025 on 10 September 2025

Ferring announces new Ambition, Enterprise Model and Executive Committee composition to accelerate…

Ferring Statement on Minirin® / Octostim® / DDAVP® / Stimate® (desmopressin) Nasal Spray

By celia in STATEMENT 2025, STATEMENT 2022 on 21 June 2022

Following the detection of out-of-specification results during testing, in 2020 Ferring initiated a precautionary voluntary global recall of all batches of the following products: Minirin® (desmopressin) Nasal Spray 0.1 mg/ml…

This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.